

**Biophytis to present at the Biotech Showcase conference
run parallel to the JP Morgan Healthcare Conference
(San Francisco, January 11-13, 2016).**

Paris (France) & Cambridge (Mass), 7 December 2015 – Biophytis (Alternext Paris: ALBPS), a geriatric medicine company advancing clinical stage drug-candidates to treat sarcopenic obesity and age related macular degeneration (AMD), announced today announced that its CEO, Stanislas Veillet, will present at the Biotech Showcase Annual Conference, to be held in San Francisco on January 11- 13, 2016.

The Biotech Showcase conference is one of the largest annual international healthcare conferences and will run parallel to the JP Morgan Healthcare Conference (San Francisco, January 11-14, 2016). Investors and biopharmaceutical executives from around the world gather in San Francisco during the second week of January at a series of events which are widely viewed as setting the tone for the coming year.

Dr Veillet's presentation at the Biotech Showcase is scheduled as follows:

Date: Tuesday, January 12, 2016

Time: 10:30 AM Track: C - Mission II (4th Floor)

Venue: Parc 55 San Francisco – Union Square 55 Cyril Magnin Street, San Francisco

Biotech Showcase™ (#BTS2016) is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its 8th year, Biotech Showcase is expected to attract upwards of 2,000 attendees.

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarcob (BIO101) to treat sarcopenic obesity and Maculia (BIO201) to treat dry age-related macular degeneration (AMD).

The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is eligible for the French PEA-PME regime.

Biophytis
Stanislas Veillet
CEO
contact@biophytis.com
Tel : +33 1 41 83 66 00

Milestones
Bruno Arabian
barabian@milestones.fr
Tel : +33 1 83 62 34 84
Mob : +33 6 87 88 47 26

LifeSci Advisors
Chris Maggos
Managing Director, Europe
chris@lifesciadvisors.com
Mob : +41 79 367 6254